Expertise in
10
conditions

Dr. Jay W. Carlson

Obstetrics and Gynecology
SJC-Women's Oncology
2055 S Fremont Ave Ste 200, 
Springfield, MO 
Expertise in
10
conditions
SJC-Women's Oncology
2055 S Fremont Ave Ste 200, 
Springfield, MO 

Overview

Jay Carlson is an Obstetrics and Gynecologist practicing medicine in Springfield, Missouri.

Dr. Carlson is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, Testicular Yolk Sac Tumor, Hysterectomy, and Lymphadenectomy.

He is actively involved in clinical research, co-authoring 9 peer reviewed articles and participating in 231 clinical trials.

Specialties

Obstetrics and Gynecology

Licenses

Obstetrics & Gynecology in MI

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

SJC-Women's Oncology
2055 S Fremont Ave Ste 200, Springfield, MO 65804

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

229 Clinical Trials

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib-S-Malate, Nivolumab, Paclitaxel
Study Phase: Phase 2
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Trametinib
Study Phase: Phase 2
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other
Study Phase: Early Phase 1
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Enrollment Status: Suspended
Publish Date: September 04, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2/Phase 3
A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers
A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Sinecatechins
Study Phase: Phase 2
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

9 Total Publications

Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
Journal: Gynecologic oncology
Published: March 17, 2024
Similar Doctors
Expertise in
17
conditions
Dr. Albert J. Bonebrake
Obstetrics and Gynecology
Expertise in
17
conditions
Dr. Albert J. Bonebrake
Obstetrics and Gynecology
Referral may be required

Grove Professional Pharmacy Inc

1001 E Primrose St, 
Springfield, MO 
 (1.6 miles away)
417-875-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Albert Bonebrake is an Obstetrics and Gynecologist practicing medicine in Springfield, Missouri. Dr. Bonebrake is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Testicular Yolk Sac Tumor, Ovarian Carcinosarcoma, Oophorectomy, and Ureteroscopy. Dr. Bonebrake is currently accepting new patients.

Expertise in
14
conditions
Dr. Marcia L. Hernandez
Obstetrics and Gynecology
Expertise in
14
conditions
Dr. Marcia L. Hernandez
Obstetrics and Gynecology
Referral may be required

Office

2115 S Fremont Ave Ste 1100, 
Springfield, MO 
 (0.1 miles away)
417-820-3554
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Marcia Hernandez is an Obstetrics and Gynecologist practicing medicine in Springfield, Missouri. She has been practicing medicine for over 17 years. Dr. Hernandez is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Malignant Mixed Mullerian Tumor, Endometrial Cancer, Endometrial Stromal Sarcoma, Vaginal Cancer, and Oophorectomy. Dr. Hernandez is currently accepting new patients.

Expertise in
12
conditions
Dr. Ashley D. Valenzuela
Obstetrics and Gynecology
Expertise in
12
conditions
Dr. Ashley D. Valenzuela
Obstetrics and Gynecology
Referral may be required

Coxhealth-Gynecologic Oncology

3850 S National Ave, 
Springfield, MO 
 (1.5 miles away)
417-875-3065
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ashley Valenzuela is an Obstetrics and Gynecologist practicing medicine in Springfield, Missouri. Dr. Valenzuela is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Malignant Mixed Mullerian Tumor, Endometrial Cancer, Cervical Cancer, Oophorectomy, and Salpingo-Oophorectomy. Dr. Valenzuela is currently accepting new patients.

Frequently Asked Questions about Dr. Jay W. Carlson

How do I make an appointment with Dr. Jay W. Carlson?

You can book an appointment with Dr. Jay W. Carlson by calling their office at 417-820-3554. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jay W. Carlson a top-rated expert for Virilizing Ovarian Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jay W. Carlson is classified as an Distinguished expert for Virilizing Ovarian Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jay W. Carlson specialize in?

While Dr. Jay W. Carlson is a Obstetrics and Gynecology, they have specific expertise in Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, and Testicular Yolk Sac Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Obstetrics and Gynecology.

Does Dr. Jay W. Carlson participate in research or clinical trials?

Yes. Dr. Jay W. Carlson has published 9 articles and abstracts on conditions like Virilizing Ovarian Tumor. You can view a list of Dr. Jay W. Carlson's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Carlson's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 21 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile